Danielle Brill
Stock Analyst at Raymond James
(1.99)
# 2,924
Out of 4,732 analysts
75
Total ratings
35.94%
Success rate
-5.63%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $14.05 | +270.11% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $40.90 | +58.92% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $21.93 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $61.53 | +28.39% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $7.37 | +144.23% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $143.26 | +8.19% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $23.86 | +50.88% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $39.05 | +2.43% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $118.00 | +27.12% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $140.55 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.08 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $422.00 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $640.52 | -5.55% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $17.57 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $38.52 | +29.80% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $32.42 | +57.31% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $58.25 | -26.17% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.60 | +733.33% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $43.84 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.57 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $14.05
Upside: +270.11%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $40.90
Upside: +58.92%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $21.93
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $61.53
Upside: +28.39%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $7.37
Upside: +144.23%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $143.26
Upside: +8.19%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $23.86
Upside: +50.88%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $39.05
Upside: +2.43%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $118.00
Upside: +27.12%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $140.55
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $7.08
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $422.00
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $640.52
Upside: -5.55%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $17.57
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $38.52
Upside: +29.80%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $32.42
Upside: +57.31%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $58.25
Upside: -26.17%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.60
Upside: +733.33%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $43.84
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.57
Upside: -